Recombinant Mouse IFN-alpha 6/IFNA6 Protein, CF Summary
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 100 μg/mL in PBS.|
|Shipping||The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Recombinant Mouse IFN-alpha 6/IFN6 (Catalog # 10207-IF) suppresses viral activity on L-929 mouse fibroblast cells infected with encephalomyocarditis (EMC) virus. The ED50 for this effect is <100 pg/mL
2 μg/lane of Recombinant Mouse IFN-alpha 6/IFNA6 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 19-22 kDa.
Background: IFN-alpha 6/IFNA6
Interferons (IFN) are a family of cytokines with potent antiviral, antiproliferative and immunomodulatory properties, classified based on their binding specificity to cell surface receptors (1). There are more than a dozen closely related IFN alpha subtypes found in both the human and mouse genome, each sharing about 80% amino acid (aa) sequence homology (2, 3). Mature mouse IFNA6 consists of 166 aa and shares 60% aa identity with human IFNA6. The type I IFNs binds to the interferon alpha receptor (IFNAR) which consists of two subunits: IFNAR1 (alpha -subunit) and IFNAR2 (beta -subunit) (4, 5). Individual IFN alpha subtypes are known to display unique efficacies to viral protection, with IFNA6 displaying the superior efficacy controlling influenza virus infection and disease (6). Treatment with IFNA6 DNA 2 weeks post‐MCMV infection proved effective at inhibiting the development of chronic autoimmune myocarditis. IFNA6 is also able to reduce chronic cardiac inflammation. These findings suggest that immunomodulation of both antiviral and autoimmune responses by IFN DNA immunization may be an avenue for improved viral immunotherapy (7, 8).
- Pestka, S. et al. (1987) Annu Rev Biochem. 56:727.
- Matsumiya, T. et al. (2007) J. Immunol. 179:4542.
- Schreiber, G. and J. Piehler (2015) Trends Immunol. 36:139.
- Fung, K.Y. et al. (2013) Science 339:1088.
- van Pesch, V. et al. (2004) J. Virol. 78:8219.
- James, C.M. et al. (2007) Vaccine. 25(10):1856.
- Bartlett, E.J. et al. (2002) Immunol. Cell Biol. 5:425.
- Bartlett, E.J. et al. (2003) Biol. Proced. 5:43.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Mouse IFN-alpha 6/IFNA6 Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Mouse IFN-alpha 6/IFNA6 Protein, CF and earn rewards!
Have you used Recombinant Mouse IFN-alpha 6/IFNA6 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image